Ardelyx (ARDX) Competitors

Ardelyx (NASDAQ:ARDX) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking.

Is ARDX or CYTK more profitable?

Ardelyx has a net margin of -28.82% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-28.82%	-46.60%	-21.49%
Cytokinetics	-17,906.25%	N/A	-50.21%

Do analysts prefer ARDX or CYTK?

Ardelyx currently has a consensus price target of $9.25, suggesting a potential upside of 84.63%. Cytokinetics has a consensus price target of $83.64, suggesting a potential upside of 82.87%. Given Ardelyx's higher possible upside, equities research analysts plainly believe Ardelyx is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cytokinetics	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.80

Which has better valuation & earnings, ARDX or CYTK?

Ardelyx has higher revenue and earnings than Cytokinetics. Ardelyx is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$124.46M	9.53	-$66.07M	-$0.30	-16.70
Cytokinetics	$3.22M	1,676.91	-$526.24M	-$5.38	-8.50

Do insiders and institutionals have more ownership in ARDX or CYTK?

58.9% of Ardelyx shares are held by institutional investors. 5.9% of Ardelyx shares are held by insiders. Comparatively, 3.4% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer ARDX or CYTK?

Cytokinetics received 278 more outperform votes than Ardelyx when rated by MarketBeat users. Likewise, 79.78% of users gave Cytokinetics an outperform vote while only 67.47% of users gave Ardelyx an outperform vote.

Company	Underperform	Outperform
Ardelyx	Outperform Votes 531 67.47%	Underperform Votes 256 32.53%
Cytokinetics	Outperform Votes 809 79.78%	Underperform Votes 205 20.22%

Which has more volatility and risk, ARDX or CYTK?

Ardelyx has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Does the media prefer ARDX or CYTK?

In the previous week, Ardelyx had 2 more articles in the media than Cytokinetics. MarketBeat recorded 15 mentions for Ardelyx and 13 mentions for Cytokinetics. Ardelyx's average media sentiment score of 0.58 beat Cytokinetics' score of 0.52 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	3 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ardelyx beats Cytokinetics on 11 of the 18 factors compared between the two stocks.